Zhejiang Dayang Biotech Group Co (003017) — Capital Reinvestment Ratio
Zhejiang Dayang Biotech Group Co (003017) has a Capital Reinvestment Ratio of 27.69x as of September 2025, meaning it reinvests 28% of its operating cash flow (CN¥638.25K) in capital expenditures (CN¥17.67 Million). See cash generation quality of Zhejiang Dayang Biotech Group Co to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Zhejiang Dayang Biotech Group Co Capital Reinvestment Ratio (2013–2025)
This chart tracks Zhejiang Dayang Biotech Group Co's Capital Reinvestment Ratio across 12 annual periods.
Annual Capital Reinvestment Ratio for Zhejiang Dayang Biotech Group Co (2013–2025)
Year-by-year Capital Reinvestment Ratio for Zhejiang Dayang Biotech Group Co from 2013 to 2025. For live market cap and broader valuation context, see Zhejiang Dayang Biotech Group Co (003017) total market value.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.48x | CN¥160.11 Million | CN¥76.38 Million | ▼ -50.2% |
| 2024 | 0.96x | CN¥66.19 Million | CN¥63.45 Million | ▲ +68.7% |
| 2023 | 0.57x | CN¥182.42 Million | CN¥103.63 Million | ▼ -50.1% |
| 2022 | 1.14x | CN¥91.89 Million | CN¥104.65 Million | ▲ +2.6% |
| 2020 | 1.11x | CN¥112.49 Million | CN¥124.82 Million | ▲ +102.9% |
| 2019 | 0.55x | CN¥113.09 Million | CN¥61.84 Million | ▼ -51.9% |
| 2018 | 1.14x | CN¥38.77 Million | CN¥44.05 Million | ▲ +106.7% |
| 2017 | 0.55x | CN¥48.64 Million | CN¥26.73 Million | ▼ -8.7% |
| 2016 | 0.60x | CN¥84.63 Million | CN¥50.95 Million | ▼ -32.4% |
| 2015 | 0.89x | CN¥48.95 Million | CN¥43.57 Million | ▲ +31.6% |
| 2014 | 0.68x | CN¥57.73 Million | CN¥39.04 Million | ▲ +50.8% |
| 2013 | 0.45x | CN¥91.64 Million | CN¥41.09 Million | — |